펩티드 치료제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)

Peptide Therapeutics Market - Scope of Report

TMR's report on the global peptide therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global peptide therapeutics market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global peptide therapeutics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the peptide therapeutics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global peptide therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global peptide therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global peptide therapeutics market.

The report delves into the competitive landscape of the global peptide therapeutics market. Key players operating in the global peptide therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global peptide therapeutics market profiled in this report.

Key Questions Answered in Global peptide therapeutics Market Report:

• What is the sales/revenue generated by peptide therapeutics across all regions during the forecast period?
• What are the opportunities in the global peptide therapeutics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Peptide Therapeutics Market - Research Objectives and Research Approach

The comprehensive report on the global peptide therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global peptide therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global peptide therapeutics market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Peptide Therapeutics Market

4. Market Overview

• 4.1. Introduction
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Peptide Therapeutics Market Analysis and Forecasts, 2023 - 2031

5. Key Insights

• 5.1. FDA-approved Peptide Therapeutics in 2022
• 5.2. Peptide Drugs Approved Since 2000, with their Targets and Indications
• 5.3. White Space Analysis
• 5.4. Porter's Analysis
• 5.5. Pipeline Analysis
• 5.6. Peptide Drugs Chemical Structure Trend Analysis
• 5.7. Separation Media Used for Peptide Drugs
• 5.8. COVID-19 Impact Analysis

6. Global Peptide Therapeutics Market Analysis and Forecasts, By Product Type

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast By Product Type, 2023 - 2031
  • 6.3.1. Innovative
  • 6.3.2. Generic
• 6.4. Market Attractiveness By Product Type

7. Global Peptide Therapeutics Market Analysis and Forecasts, By Application

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast By Application, 2023 - 2031
  • 7.3.1. Metabolic
  • 7.3.2. Oncology
  • 7.3.3. Gastrointestinal
  • 7.3.4. Cardiovascular
  • 7.3.5. Neurological
  • 7.3.6. Others
• 7.4. Market Attractiveness By Application

8. Global Peptide Therapeutics Market Analysis and Forecasts, By Route of Administration

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast By Route of Administration, 2023 - 2031
  • 8.3.1. Parenteral
  • 8.3.2. Oral
  • 8.3.3. Others
• 8.4. Market Attractiveness By Route of Administration

9. Global Peptide Therapeutics Market Analysis and Forecasts, By Types of Peptide

• 9.1. Introduction & Definition
• 9.2. Key Findings / Developments
• 9.3. Market Value Forecast By Types of Peptide, 2023 - 2031
  • 9.3.1. Native Peptides
  • 9.3.2. Analog Peptides
  • 9.3.3. Heterologous Peptides
• 9.4. Market Attractiveness By Types of Peptide

10. Global Peptide Therapeutics Market Analysis and Forecasts, By Technology

• 10.1. Introduction & Definition
• 10.2. Key Findings / Developments
• 10.3. Market Value Forecast By Technology, 2023 - 2031
  • 10.3.1. Liquid Phase
  • 10.3.2. Solid Phase
  • 10.3.3. Hybrid
• 10.4. Market Attractiveness By Technology

11. Global Peptide Therapeutics Market Analysis and Forecasts, By Manufacturing Type

• 11.1. Introduction & Definition
• 11.2. Key Findings / Developments
• 11.3. Market Value Forecast By Manufacturing Type,2023 - 2031
  • 11.3.1. In-house
  • 11.3.2. CMO
• 11.4. Market Attractiveness By Manufacturing Type

12. Global Peptide Therapeutics Market Analysis and Forecasts, By Region

• 12.1. Key Findings
• 12.2. Market Value Forecast By Region
  • 12.2.1. North America
  • 12.2.2. Europe
  • 12.2.3. Asia Pacific
  • 12.2.4. Latin America
  • 12.2.5. Middle East & Africa
• 12.3. Market Attractiveness By Country/Region

13. North America Peptide Therapeutics Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast By Product Type,2023 - 2031
  • 13.2.1. Innovative
  • 13.2.2. Generic
• 13.3. Market Value Forecast By Application,2023 - 2031
  • 13.3.1. Metabolic
  • 13.3.2. Oncology
  • 13.3.3. Gastrointestinal
  • 13.3.4. Cardiovascular
  • 13.3.5. Neurological
  • 13.3.6. Others
• 13.4. Market Value Forecast By Route of Administration,2023 - 2031
  • 13.4.1. Parenteral
  • 13.4.2. Oral
  • 13.4.3. Others
• 13.5. Market Value Forecast By Types of Peptide,2023 - 2031
  • 13.5.1. Native Peptides
  • 13.5.2. Analog Peptides
  • 13.5.3. Heterologous Peptides
• 13.6. Market Value Forecast By Technology,2023 - 2031
  • 13.6.1. Liquid Phase
  • 13.6.2. Solid Phase
  • 13.6.3. Hybrid
• 13.7. Market Value Forecast By Manufacturing Type,2023 - 2031
  • 13.7.1. In-house
  • 13.7.2. CMO
• 13.8. Market Value Forecast By Country,2023 - 2031
  • 13.8.1. U.S.
  • 13.8.2. Canada
• 13.9. Market Attractiveness Analysis
  • 13.9.1. By Product Type
  • 13.9.2. By Application
  • 13.9.3. By Route of Administration
  • 13.9.4. By Types of Peptide
  • 13.9.5. By Technology
  • 13.9.6. By Manufacturing Type
  • 13.9.7. By Country

14. Europe Peptide Therapeutics Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast By Product Type,2023 - 2031
  • 14.2.1. Innovative
  • 14.2.2. Generic
• 14.3. Market Value Forecast By Application,2023 - 2031
  • 14.3.1. Metabolic
  • 14.3.2. Oncology
  • 14.3.3. Gastrointestinal
  • 14.3.4. Cardiovascular
  • 14.3.5. Neurological
  • 14.3.6. Others
• 14.4. Market Value Forecast By Route of Administration,2023 - 2031
  • 14.4.1. Parenteral
  • 14.4.2. Oral
  • 14.4.3. Others
• 14.5. Market Value Forecast By Types of Peptide,2023 - 2031
  • 14.5.1. Native Peptides
  • 14.5.2. Analog Peptides
  • 14.5.3. Heterologous Peptides
• 14.6. Market Value Forecast By Technology,2023 - 2031
  • 14.6.1. Liquid Phase
  • 14.6.2. Solid Phase
  • 14.6.3. Hybrid
• 14.7. Market Value Forecast By Manufacturing Type,2023 - 2031
  • 14.7.1. In-house
  • 14.7.2. CMO
• 14.8. Market Value Forecast By Country,2023 - 2031
  • 14.8.1. Germany
  • 14.8.2. U.K.
  • 14.8.3. France
  • 14.8.4. Spain
  • 14.8.5. Italy
  • 14.8.6. Rest of Europe
• 14.9. Market Attractiveness Analysis
  • 14.9.1. By Product Type
  • 14.9.2. By Application
  • 14.9.3. By Route of Administration
  • 14.9.4. By Types of Peptide
  • 14.9.5. By Technology
  • 14.9.6. By Manufacturing Type
  • 14.9.7. By Country

15. Asia Pacific Peptide Therapeutics Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast By Product Type,2023 - 2031
  • 15.2.1. Innovative
  • 15.2.2. Generic
• 15.3. Market Value Forecast By Application,2023 - 2031
  • 15.3.1. Metabolic
  • 15.3.2. Oncology
  • 15.3.3. Gastrointestinal
  • 15.3.4. Cardiovascular
  • 15.3.5. Neurological
  • 15.3.6. Others
• 15.4. Market Value Forecast By Route of Administration,2023 - 2031
  • 15.4.1. Parenteral
  • 15.4.2. Oral
  • 15.4.3. Others
• 15.5. Market Value Forecast By Types of Peptide,2023 - 2031
  • 15.5.1. Native Peptides
  • 15.5.2. Analog Peptides
  • 15.5.3. Heterologous Peptides
• 15.6. Market Value Forecast By Technology,2023 - 2031
  • 15.6.1. Liquid Phase
  • 15.6.2. Solid Phase
  • 15.6.3. Hybrid
• 15.7. Market Value Forecast By Manufacturing Type,2023 - 2031
  • 15.7.1. In-house
  • 15.7.2. CMO
• 15.8. Market Value Forecast By Country,2023 - 2031
  • 15.8.1. China
  • 15.8.2. Japan
  • 15.8.3. India
  • 15.8.4. Australia & New Zealand
  • 15.8.5. Rest of Asia Pacific
• 15.9. Market Attractiveness Analysis
  • 15.9.1. By Product Type
  • 15.9.2. By Application
  • 15.9.3. By Route of Administration
  • 15.9.4. By Types of Peptide
  • 15.9.5. By Technology
  • 15.9.6. By Manufacturing Type
  • 15.9.7. By Country

16. Latin America Peptide Therapeutics Market Analysis and Forecast

• 16.1. Introduction
  • 16.1.1. Key Findings
• 16.2. Market Value Forecast By Product Type,2023 - 2031
  • 16.2.1. Innovative
  • 16.2.2. Generic
• 16.3. Market Value Forecast By Application,2023 - 2031
  • 16.3.1. Metabolic
  • 16.3.2. Oncology
  • 16.3.3. Gastrointestinal
  • 16.3.4. Cardiovascular
  • 16.3.5. Neurological
  • 16.3.6. Others
• 16.4. Market Value Forecast By Route of Administration,2023 - 2031
  • 16.4.1. Parenteral
  • 16.4.2. Oral
  • 16.4.3. Others
• 16.5. Market Value Forecast By Types of Peptide,2023 - 2031
  • 16.5.1. Native Peptides
  • 16.5.2. Analog Peptides
  • 16.5.3. Heterologous Peptides
• 16.6. Market Value Forecast By Technology,2023 - 2031
  • 16.6.1. Liquid Phase
  • 16.6.2. Solid Phase
  • 16.6.3. Hybrid
• 16.7. Market Value Forecast By Manufacturing Type,2023 - 2031
  • 16.7.1. In-house
  • 16.7.2. CMO
• 16.8. Market Value Forecast By Country,2023 - 2031
  • 16.8.1. Brazil
  • 16.8.2. Mexico
  • 16.8.3. Rest of Latin America
• 16.9. Market Attractiveness Analysis
  • 16.9.1. By Product Type
  • 16.9.2. By Application
  • 16.9.3. By Route of Administration
  • 16.9.4. By Types of Peptide
  • 16.9.5. By Technology
  • 16.9.6. By Manufacturing Type
  • 16.9.7. By Country

17. Middle East & Africa Peptide Therapeutics Market Analysis and Forecast

• 17.1. Introduction
  • 17.1.1. Key Findings
• 17.2. Market Value Forecast By Product Type,2023 - 2031
  • 17.2.1. Innovative
  • 17.2.2. Generic
• 17.3. Market Value Forecast By Application,2023 - 2031
  • 17.3.1. Metabolic
  • 17.3.2. Oncology
  • 17.3.3. Gastrointestinal
  • 17.3.4. Cardiovascular
  • 17.3.5. Neurological
  • 17.3.6. Others
• 17.4. Market Value Forecast By Route of Administration,2023 - 2031
  • 17.4.1. Parenteral
  • 17.4.2. Oral
  • 17.4.3. Others
• 17.5. Market Value Forecast By Types of Peptide,2023 - 2031
  • 17.5.1. Native Peptides
  • 17.5.2. Analog Peptides
  • 17.5.3. Heterologous Peptides
• 17.6. Market Value Forecast By Technology,2023 - 2031
  • 17.6.1. Liquid Phase
  • 17.6.2. Solid Phase
  • 17.6.3. Hybrid
• 17.7. Market Value Forecast By Manufacturing Type,2023 - 2031
  • 17.7.1. In-house
  • 17.7.2. CMO
• 17.8. Market Value Forecast By Country,2023 - 2031
  • 17.8.1. GCC Countries
  • 17.8.2. South Africa
  • 17.8.3. Rest of Middle East & Africa
• 17.9. Market Attractiveness Analysis
  • 17.9.1. By Product Type
  • 17.9.2. By Application
  • 17.9.3. By Route of Administration
  • 17.9.4. By Types of Peptide
  • 17.9.5. By Technology
  • 17.9.6. By Manufacturing Type
  • 17.9.7. By Country

18. Competition Landscape

• 18.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 18.2. Market Share Analysis By Company (2022)
• 18.3. Company Profiles
  • 18.3.1. Amgen, Inc.
    • 18.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 18.3.1.2. Product Portfolio
    • 18.3.1.3. Financial Overview
    • 18.3.1.4. SWOT Analysis
    • 18.3.1.5. Strategic Overview
  • 18.3.2. Sachem Holding AG
    • 18.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 18.3.2.2. Product Portfolio
    • 18.3.2.3. Financial Overview
    • 18.3.2.4. SWOT Analysis
    • 18.3.2.5. Strategic Overview
  • 18.3.3. Eli Lilly and Company
    • 18.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 18.3.3.2. Product Portfolio
    • 18.3.3.3. Financial Overview
    • 18.3.3.4. SWOT Analysis
    • 18.3.3.5. Strategic Overview
  • 18.3.4. F. Hoffmann-La Roche Ltd.
    • 18.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 18.3.4.2. Product Portfolio
    • 18.3.4.3. Financial Overview
    • 18.3.4.4. SWOT Analysis
    • 18.3.4.5. Strategic Overview
  • 18.3.5. GlaxoSmithKline plc
    • 18.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 18.3.5.2. Product Portfolio
    • 18.3.5.3. Financial Overview
    • 18.3.5.4. SWOT Analysis
    • 18.3.5.5. Strategic Overview
  • 18.3.6. Novartis AG
    • 18.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 18.3.6.2. Product Portfolio
    • 18.3.6.3. Financial Overview
    • 18.3.6.4. SWOT Analysis
    • 18.3.6.5. Strategic Overview
  • 18.3.7. Pfizer, Inc.
    • 18.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 18.3.7.2. Product Portfolio
    • 18.3.7.3. Financial Overview
    • 18.3.7.4. SWOT Analysis
    • 18.3.7.5. Strategic Overview
  • 18.3.8. Sanofi
    • 18.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 18.3.8.2. Product Portfolio
    • 18.3.8.3. Financial Overview
    • 18.3.8.4. SWOT Analysis
    • 18.3.8.5. Strategic Overview
  • 18.3.9. Takeda Pharmaceutical Company Limited
    • 18.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 18.3.9.2. Product Portfolio
    • 18.3.9.3. Financial Overview
    • 18.3.9.4. SWOT Analysis
    • 18.3.9.5. Strategic Overview
  • 18.3.10. Teva Pharmaceutical Industries Ltd.
    • 18.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 18.3.10.2. Product Portfolio
    • 18.3.10.3. Financial Overview
    • 18.3.10.4. SWOT Analysis
    • 18.3.10.5. Strategic Overview